Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Cancer Res. 2020 May 4;80(15):3088–3100. doi: 10.1158/0008-5472.CAN-18-3825

Figure 2. IL-26 is overexpressed in TNBC and is directly produced by tumor cells.

Figure 2.

A) Stratifying TCGA BC dataset by molecular subtype reveals that Basal-like tumors are significantly enriched for IL-26 compared to other molecular subtypes (Total= 981 BCs; Luminal A n=499; Luminal B n=197; Her2-enriched n=78; Normal-like n=36; Basal-like n=171). B) RNAscope analysis of a BC Progression Tissue Microarray for IL-26 mRNA detected significantly more IL-26 transcripts compared to all other BCs (Non-TNBC n=107; TNBC n=23). C) Representative images of RNAscope results on tissue microarrays for both TNBC and Non-TNBC tumors. Tumor cell clusters are indicated with dashed lines. Nuclei (Dapi) are indicated in grey and IL-26 is indicated by yellow. D) Single-cell RNA profiling of TNBC patients (GSE110686), Group 6 indicated. E) Expression profile of IL-26 among different CD45+ groups identified in patient TNBC samples. Bars indicate SEM and ** p < 0.01, **** p < 0.0001.